Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics

Radiation Induced Esophagitis Market Forecast-2032 report offers an in-depth understanding of the Radiation Induced Esophagitis, historical and forecasted epidemiology as well as the Radiation Induced Esophagitis market trends in the 7MM.
DelveInsight's "Radiation Induced Esophagitis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Radiation Induced Esophagitis, historical and forecasted epidemiology as well as the Radiation Induced Esophagitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Radiation Induced Esophagitis, offering comprehensive insights into the Radiation Induced Esophagitis revenue trends, prevalence, and treatment landscape. The report delves into key Radiation Induced Esophagitis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Radiation Induced Esophagitis therapies. Additionally, we cover the landscape of Radiation Induced Esophagitis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Radiation Induced Esophagitis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Radiation Induced Esophagitis space.

To Know in detail about the Radiation Induced Esophagitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Radiation Induced Esophagitis Market Forecast [https://www.delveinsight.com/sample-request/radiation-induced-esophagitis-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Radiation Induced Esophagitis Market Report:

*
The Radiation Induced Esophagitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In November 2024, Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotech company focused on precision drug delivery for conditions with high unmet needs, has announced further positive clinical results from its RESOLVE Phase 1b/2a trial, assessing the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (EoE).

*
In August 2023, Galera Therapeutics announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its New Drug Application (NDA) for avasopasem manganese, intended for the treatment of radiotherapy-induced severe oral mucositis (SOM) in head and neck cancer patients undergoing standard-of-care therapy.

*
Radiation-induced esophagitis can be categorized into acute and late types. Acute radiation esophagitis occurs within 3 months of therapy, while late radiation esophagitis develops more than 3 months after treatment. Typically, acute cases appear within 2 to 3 weeks following initial treatment, whereas late cases emerge around 6 months later.

*
Approximately 5% of patients who underwent radiation therapy at a dose of 60 Gray (Gy) experienced late complications.

*
Current treatments for radiation-induced esophagitis primarily aim at managing symptoms, such as pain relief, anti-inflammatory medications, and nutritional support, rather than targeting the root cause of inflammation and damage to the esophageal tissue.

*
Key Radiation Induced Esophagitis Companies: Galera Therapeutics, and others

*
Key Radiation Induced Esophagitis Therapies: Avasopasem Manganese, and others

*
The Radiation Induced Esophagitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Radiation Induced Esophagitis pipeline products will significantly revolutionize the Radiation Induced Esophagitis market dynamics.

*
In 2023, there were 60,000 cases of radiation-induced esophagitis across the 7MM, with the United States accounting for approximately 43% of the total cases, representing the highest number of cases.

*
Germany had the highest incidence of radiation-induced esophagitis cases among the EU4 and the UK, followed by the UK.

*
Individuals over the age of 70 are at a higher risk of developing radiation-induced esophagitis.

*
Radiation-induced esophagitis occurs more frequently in women than in men.

Radiation Induced Esophagitis Overview

Radiation-induced esophagitis is inflammation of the esophagus caused by radiation therapy, commonly used in the treatment of cancers such as lung, breast, or head and neck cancers. The radiation damages the lining of the esophagus, leading to symptoms like pain, difficulty swallowing, chest discomfort, and acid reflux. It typically develops during or shortly after radiation treatment and can range from mild irritation to severe complications. Treatment focuses on managing symptoms and preventing further damage, often through medications like anti-inflammatory drugs, pain relievers, and modifications in diet.

Get a Free sample for the Radiation Induced Esophagitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/radiation-induced-esophagitis-market-forecast [https://www.delveinsight.com/report-store/radiation-induced-esophagitis-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Radiation Induced Esophagitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Radiation Induced Esophagitis Epidemiology Segmentation:

The Radiation Induced Esophagitis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Radiation Induced Esophagitis

*
Prevalent Cases of Radiation Induced Esophagitis by severity

*
Gender-specific Prevalence of Radiation Induced Esophagitis

*
Diagnosed Cases of Episodic and Chronic Radiation Induced Esophagitis

Download the report to understand which factors are driving Radiation Induced Esophagitis epidemiology trends @ Radiation Induced Esophagitis Epidemiology Forecast [https://www.delveinsight.com/sample-request/radiation-induced-esophagitis-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Radiation Induced Esophagitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Radiation Induced Esophagitis market or expected to get launched during the study period. The analysis covers Radiation Induced Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Radiation Induced Esophagitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Radiation Induced Esophagitis Therapies and Key Companies

*
Avasopasem Manganese: Galera Therapeutics

Discover more about therapies set to grab major Radiation Induced Esophagitis market share @ Radiation Induced Esophagitis Treatment Landscape [https://www.delveinsight.com/sample-request/radiation-induced-esophagitis-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Radiation Induced Esophagitis Market Drivers

*
Rising Cancer Incidences

*
Advancements in Radiation Therapy

*
Growing Focus on Symptom Management

*
Approval of New Therapies

*
Increased Research Funding

Radiation Induced Esophagitis Market Barriers

*
High Treatment Costs:

*
Limited Awareness

*
Side Effects of Current Treatments

*
Lack of Targeted Therapies

*
Regulatory Challenges

Scope of the Radiation Induced Esophagitis Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Radiation Induced Esophagitis Companies: Galera Therapeutics, and others

*
Key Radiation Induced Esophagitis Therapies: Avasopasem Manganese, and others

*
Radiation Induced Esophagitis Therapeutic Assessment: Radiation Induced Esophagitis current marketed and Radiation Induced Esophagitis emerging therapies

*
Radiation Induced Esophagitis Market Dynamics: Radiation Induced Esophagitis market drivers and Radiation Induced Esophagitis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Radiation Induced Esophagitis Unmet Needs, KOL's views, Analyst's views, Radiation Induced Esophagitis Market Access and Reimbursement

To know more about Radiation Induced Esophagitis companies working in the treatment market, visit @ Radiation Induced Esophagitis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/radiation-induced-esophagitis-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Radiation Induced Esophagitis Market Report Introduction

2. Executive Summary for Radiation Induced Esophagitis

3. SWOT analysis of Radiation Induced Esophagitis

4. Radiation Induced Esophagitis Patient Share (%) Overview at a Glance

5. Radiation Induced Esophagitis Market Overview at a Glance

6. Radiation Induced Esophagitis Disease Background and Overview

7. Radiation Induced Esophagitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Radiation Induced Esophagitis

9. Radiation Induced Esophagitis Current Treatment and Medical Practices

10. Radiation Induced Esophagitis Unmet Needs

11. Radiation Induced Esophagitis Emerging Therapies

12. Radiation Induced Esophagitis Market Outlook

13. Country-Wise Radiation Induced Esophagitis Market Analysis (2019-2032)

14. Radiation Induced Esophagitis Market Access and Reimbursement of Therapies

15. Radiation Induced Esophagitis Market Drivers

16. Radiation Induced Esophagitis Market Barriers

17. Radiation Induced Esophagitis Appendix

18. Radiation Induced Esophagitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=radiation-induced-esophagitis-market-set-to-grow-substantially-through-2032-delveinsight-projects-galera-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.